Novo Nordisk has announced a wide-ranging strategic partnership with OpenAI, marking one of the most ambitious AI integration programmes yet seen in the pharmaceutical sector as the Danish drugmaker seeks to maintain its edge in the fiercely competitive obesity and diabetes markets.
The agreement, announced this morning, will see OpenAI's advanced AI models deployed across Novo Nordisk's global operations — spanning research and development, manufacturing, supply chain and distribution, as well as commercial functions.
Pilot programmes are already being launched across R&D, manufacturing and commercial operations, with full integration across the business expected before the end of the year.
Central to the partnership is the application of AI to accelerate drug discovery.
Novo says the technology will be used to analyse complex datasets at a scale previously not possible, identify promising drug candidates and reduce the time required to move therapies from bench to patient.
The company is particularly focused on finding new treatment options for the millions of people living with obesity and diabetes worldwide.
Mike Doustdar, president and CEO of Novo Nordisk, said the partnership "is one important step in positioning Novo Nordisk to lead in the next era of healthcare," adding that AI integration would allow the company to "identify patterns we could not see and test hypotheses faster than ever."
Beyond the lab, OpenAI will also work with Novo Nordisk on upskilling its global workforce and improving AI literacy across the organisation, as well as driving efficiency improvements in manufacturing, supply chain and distribution.
The partnership has been structured with strict data protection, governance frameworks and human oversight to ensure ethical and regulatory compliance.
Sam Altman, CEO of OpenAI, described the collaboration as an opportunity to "help people live better, longer lives," saying it would enable Novo Nordisk to "accelerate scientific discovery, run smarter global operations and redefine the future of patient care."
The deal follows Novo Nordisk's existing AI collaboration with NVIDIA on generative AI for target and drug discovery and extends OpenAI's growing presence in life sciences — the company has previously signed agreements with Eli Lilly, Sanofi/Formation Bio and Moderna.